Multi-omics and management of follicular carcinoma of the thyroid

dc.contributor.authorLuvhengo, Thifhelimbilu Emmanuel
dc.contributor.authorBombil, Ifongo
dc.contributor.authorMokhtari, Arian
dc.contributor.authorMoeng, Maeyane Stephens
dc.contributor.authorDemetriou, Demetra Danielle
dc.contributor.authorSanders, Claire
dc.contributor.authorDlamini, Zodwa
dc.contributor.emailzodwa.dlamini@up.ac.zaen_US
dc.date.accessioned2024-03-18T04:35:03Z
dc.date.available2024-03-18T04:35:03Z
dc.date.issued2023-04-19
dc.description.abstractFollicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland, accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The diagnostic work-up, staging, risk stratification, management, and follow-up strategies in patients who have FTC are modeled after those of papillary thyroid carcinoma (PTC), even though FTC is more aggressive. FTC has a greater propensity for haematogenous metastasis than PTC. Furthermore, FTC is a phenotypically and genotypically heterogeneous disease. The diagnosis and identification of markers of an aggressive FTC depend on the expertise and thoroughness of pathologists during histopathological analysis. An untreated or metastatic FTC is likely to de-differentiate and become poorly differentiated or undifferentiated and resistant to standard treatment. While thyroid lobectomy is adequate for the treatment of selected patients who have low-risk FTC, it is not advisable for patients whose tumor is larger than 4 cm in diameter or has extensive extra-thyroidal extension. Lobectomy is also not adequate for tumors that have aggressive mutations. Although the prognosis for over 80% of PTC and FTC is good, nearly 20% of the tumors behave aggressively. The introduction of radiomics, pathomics, genomics, transcriptomics, metabolomics, and liquid biopsy have led to improvements in the understanding of tumorigenesis, progression, treatment response, and prognostication of thyroid cancer. The article reviews the challenges that are encountered during the diagnostic workup, staging, risk stratification, management, and follow-up of patients who have FTC. How the application of multi-omics can strengthen decision-making during the management of follicular carcinoma is also discussed.en_US
dc.description.departmentMedical Oncologyen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council (SAMRC) and the National Research Foundation (NRF).en_US
dc.description.urihttps://www.mdpi.com/journal/biomedicinesen_US
dc.identifier.citationLuvhengo, T.E.; Bombil, I.; Mokhtari, A.; Moeng, M.S.; Demetriou, D.; Sanders, C.; Dlamini, Z. Multi-Omics and Management of Follicular Carcinoma of the Thyroid. Biomedicines 2023, 11, 1217. https://DOI.org/10.3390/biomedicines11041217.en_US
dc.identifier.issn2227-9059
dc.identifier.other10.3390/biomedicines11041217
dc.identifier.urihttp://hdl.handle.net/2263/95245
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectFollicular carcinomaen_US
dc.subjectGenomicsen_US
dc.subjectMulti-omicsen_US
dc.subjectPathomicsen_US
dc.subjectRadiomicsen_US
dc.subjectTranscriptomicsen_US
dc.subjectTreatmenten_US
dc.subjectFollicular thyroid carcinoma (FTC)en_US
dc.subjectPapillary thyroid carcinoma (PTC)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleMulti-omics and management of follicular carcinoma of the thyroiden_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Luvhengo_MultiOmics_2023.pdf
Size:
1.97 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: